Key insights
- Piper Sandler reiterated an Overweight rating on Globus Medical (GMED), citing a new patent filing for a next-generation robot that could enhance competitive positioning against rivals like Medtronic. The patent details suggest advanced features, potentially accelerating product development. Strong Q1 2026 earnings and revenue also beat expectations, reinforcing the company's growth trajectory and market leadership in the spine sector. This news suggests positive near-term momentum for GMED shares.
Investing.com - Piper Sandler reiterated an Overweight rating and $115.00 price target on Globus Medical (NYSE:GMED) shares Tuesday. With the stock currently trading at $78.83, this represents significant upside potential. According to InvestingPro analysis, the company appears undervalued based on its Fair Value assessment, with 12 analysts having recently revised their earnings upwards for the upcoming period.
The firm noted it discovered a new patent filing from Globus Medical describing a next-generation Excelsius robot. Piper Sandler stated that a patent does not always yield a new product and management would not comment on it specifically.
The information disclosed appeared extremely robust and detailed, leading the firm to believe the company could be farther along in the process than expected. Piper Sandler said Medtronic’s recent approval of the next-gen AXiS robot should provide Globus additional ammunition to combat potential competitive pressures and perhaps a replacement cycle, which is an area of concern for investors.
Several features of the proposed device are extremely compelling, including its time-efficient, radiation-free workflow and enhanced soft tissue and nerve sensing capabilities, which AXiS doesn’t have, according to the firm.
Piper Sandler expects Globus Medical remains a technology leader in the space, enabling the company to capture further share in the large global spine market. The company’s strong fundamentals are reflected in its 23% revenue growth and robust 68% gross profit margin. For deeper insights, investors can access a comprehensive Pro Research Report on GMED, one of 1,400+ US equities covered with expert analysis and actionable intelligence.
In other recent news, Globus Medical reported strong financial results for the first quarter of 2026, with earnings per share (EPS) reaching $1.12, which surpassed forecasts of $0.92 by 21.8%. The company’s revenue also exceeded expectations, coming in at $759.9 million compared to the anticipated $740.3 million. Following these results, Needham raised its price target for Globus Medical to $117, while maintaining a Buy rating, noting that management increased its 2026 EPS guidance by approximately 7% at the midpoint. Stifel also raised its price target to $95 from $90, highlighting strong core Musculoskeletal performance. Freedom Broker, however, lowered its price target to $87, despite acknowledging that the earnings exceeded estimates in several areas. Citizens reiterated a Market Perform rating, citing a 26% year-over-year constant currency growth in revenue. These developments reflect a mixed reaction from analysts, with varying price targets and ratings based on the company’s recent performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates GMED alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if GMED is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?